GigaStar Market facilitates a second $1M+ raise for a YouTube Channel.

CHICAGO, April 9, 2025 /PRNewswire/ — GigaStar, the marketplace bringing YouTube Creators and Investors together, has announced the record-breaking close of a $1.3 million Regulation Crowdfunding (Reg CF) offering. This marks the largest known raise by a YouTube Creator in exchange for a percentage of potential future channel revenue.*

*Investment offerings are speculative, illiquid, and involve risks, including the risk of loss of the entire investment.

The raise, which was completely sold out, was led by Jason Boehlke, the Creator behind the popular Mr. Hand Pay YouTube channel. The offering attracted over 1,200 investors eager to back one of YouTube’s fastest-growing channels in the gaming and casino space.

This milestone represents the second successful raise of over $1 million by a Creator on GigaStar Market, further establishing the platform as a powerful new capital-raising model for the Creator Economy.

“This raise proves that Creators like me can build something bigger by inviting our communities to join us as partners in our journey,” said Jason Boehlke. “GigaStar gave me the innovative platform to engage my audience.”**

GigaStar has also invited Boehlke to join its DropStars Program, an invite-only advisory board for top Creators who align with GigaStar’s values and vision to fuel human creativity.

“With this raise, Jason has set a new benchmark for the scalability of investments in Creator-driven content,” said GigaStar CEO Hazem Dawani. “We’re also thrilled to welcome him into our DropStars Program.”

As more Creators seek alternative funding models outside of traditional sponsorships or loans, GigaStar Market is uniquely positioned to meet the growing demand for scalable, revenue-sharing monetization, facilitated on an SEC-registered crowdfunding platform.

Learn more about investment opportunities in other YouTube channels at gigastar.io.

About GigaStar
GigaStar fuels human creativity by bringing Creators and Investors together. GigaStar provides Creators with an intuitive platform to raise capital from thousands of Investors who share in the channel’s potential future YouTube revenue while supporting a Creator’s journey. Learn more at gigastar.io.

**The persons providing the testimonials have experience in the services of GigaStar Market. Their respective experience may not be representative of all other Clients. Testimonials are not paid for by GigaStar Market and do not constitute a guarantee of future performance or success related to any product, transaction, or service.

Creator Networks, Inc., (dba GigaStar) is the Parent Company of GigaStar Portal, LLC (dba GigaStar Market). GigaStar Market is an SEC-registered funding portal and a member of FINRA offering securities under Reg CF. Investment offerings are speculative, illiquid, and involve risks, including the risk of loss of the entire investment. The past performance of an offering, security, or channel is not a guarantee of future results. The content herein does not constitute a solicitation of an offer to buy security(ies).

View original content to download multimedia:https://www.prnewswire.com/news-releases/youtube-creator-breaks-record-with-1-3m-raise-on-gigastar-market-302422413.html

SOURCE GigaStar

SUN VALLEY, Idaho, April 9, 2025 /PRNewswire/ — Cold Summit, a leading developer of next-generation cold storage solutions, is pleased to announce the expansion of its operations into Europe with the formation of Cold Summit Europe. To lead this strategic initiative, the company has appointed Harld Peters as President of Cold Summit Europe.

Harld brings over 30 years of international experience in global supply chain management and the services industry, having held senior leadership roles at top companies such as UPS and, most recently, serving as President of Lineage Europe. He has led large-scale operations across High-tech, FMCG, Pharma, and Food sectors, with deep expertise in contract logistics, freight forwarding, transportation, and small package delivery. His global career spans multiple countries and continents, making him exceptionally well-equipped to lead Cold Summit’s expansion into Europe.

“Harld’s deep industry expertise and global perspective make him the ideal leader to drive our expansion into the European cold chain market,” said Scott Pertel, CEO of Cold Summit. “His proven ability to align vision with execution and deliver growth across complex logistics environments will be instrumental as we scale our presence and service offerings across Europe.”

“I am honored to join Cold Summit at this exciting stage of growth,” said Harld Peters. “The demand for modern, efficient, and sustainable cold storage solutions in Europe is significant, and Cold Summit is well-positioned to deliver value to a broad range of clients. I look forward to leading our expansion and building a strong presence across the region.”

With this move, Cold Summit continues its mission of Reshaping the Global Cold Chain industry through innovation, client-centric design, and energy-efficient infrastructure. Expansion into Europe marks a major milestone in the company’s growth and commitment to delivering excellence in cold storage solutions worldwide.

About Cold Summit
Cold Summit is a developer of innovative, high-performance cold storage and logistics facilities designed to meet the evolving needs of the food, pharmaceutical, and logistics sectors. Headquartered in Sun Valley, Idaho, with offices in Florida, Virginia, and Amsterdam, Cold Summit delivers full-service solutions from advisory and development through construction and operations.

www.coldsummit.com 

Photo – https://mma.prnewswire.com/media/2658469/Cold_Summit_Port_of_Wilmington.jpg

Logo – https://mma.prnewswire.com/media/2658468/Cold_Summit_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/cold-summit-announces-european-expansion-and-appoints-harld-peters-as-president-of-cold-summit-europe-302422324.html

Cytora’s proprietary oral mucosa stem cells treatment holds potential to be a game changer in the field of stem cell therapy

YOKNEAM, Israel, April 9, 2025 /PRNewswire/ — Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSCs), reported today successful results of a Phase 1/2a clinical trial for treating chronic hard to heal diabetic foot ulcers (DFUs) with its leading allogeneic off-the-shelf cell therapy product, hOMSC200. The study results show that hOMSC200 is safe and did not elicit any immune response in recipients. In addition, hOMSC200 was shown to be significantly more effective than the standard of care procedure in treating DFUs.

“Cytora’s unique patented technology, based on oral mucosa stem cells, holds a potential to be a game changer in the field of stem cell therapy,” stated Prof. Sandu Pitaru, Co-Founder and CTO of Cytora. “We are at the forefront of cell therapy, leveraging a proprietary unique stem cell population discovered in the human oral mucosa. Notably, the embryonic origin of this population is a primordial tissue of the developing embryonic brain. These unique stem cells retain in the adult’s oral mucosa the properties of neural and other stem cell types, making them effective in targeting chronic multifaceted diseases, such as chronic wounds, and neurodegenerative and autoimmune diseases. Our Phase 1/2a clinical trial has demonstrated that the use of this stem cell population in humans is safe and effective in treating hard to heal diabetic foot ulcers.”

“We are extremely pleased and encouraged by the remarkable results we saw in this Phase 1/2a trial,” said Yona Geffen, PhD, CEO of Cytora. “Diabetic foot ulcers are a common complication of diabetes and are extremely difficult to treat, leading to significant morbidity. We are targeting the DFU patient population that do not respond to available treatment options. This study enrolled 21 subjects with a mean wound duration of over 2 years, and our results clearly show that not only is hOMCS200 safe for use, with no recorded adverse events or immunological response to the injected cells, but it is also highly effective. The results of this trial put us on solid footing for applying for an IND during the second half of 2025 that will enable starting a large-scale Phase 2 trial for treating DFUs during 2026.”

The Phase 1/2a trial was a single center, randomized, partially blinded study, comprising two hOMSC200 dose groups (low and high) and one placebo treated group of DFU patients. The study enrolled 21 patients with a mean wound duration of 27 months. Subjects received a single administration of either a high or low dose of hOMSC200 or a placebo and were followed up for 18 months. All subjects also received standard of wound care treatments. The primary end point was safety, including treatment-related adverse events and immunological rejection reactions towards the injected cells. Secondary end points included partial and complete wound closure rate.

Results show no recorded adverse events, and no humoral or cellular immune response elicited by the injected cells. The proportion of complete wound closure was higher in the hOMSC200-treated patients in comparison to placebo in all populations, with no significant difference between the low and high dose groups. In the intent to treat (ITT) analysis, there was a 53% wound closure rate in the treatment group versus a 33% wound closure rate in the placebo group. In the per protocol group, which included 12 patients who adhered to protocol guidelines, there was a 100% success rate, versus a 20% success rate of wound closure in the placebo control group.

About Human Oral Mucosa Stem cells (hOMSCs)1

Cytora’s patented and transformative stem cell platform is based on the discovery of a novel and unique stem cell population in the oral mucosa termed human Oral Mucosa Stem Cells (hOMSC). hOMSCs are a unique population of stem cells originating from the neural crest. In the oral cavity, they mediate rapid wound healing compared to other tissues, promote full tissue regeneration, without scarring, and their activity is not affected by age. In addition, this remarkable pattern of wound healing is negligibly affected by diabetes, which is notorious for impeding wound healing in other locations of the body, primarily in the foot.

Cytora has shown that hOMSCs are easily propagated without losing their unique stem-cell properties – a tiny biopsy of 4x3x2 mm from a healthy donor generates doses for thousands of treatments. These cells combine a high therapeutic potency with an excellent safety profile, and do not elicit immune rejection when transplanted in allogeneic recipients, thus enabling the production of an “off the shelf” stem cell treatment platform for human use.

About Diabetic Foot Ulcers

Diabetic foot ulcers (DFUs) are open sores or wounds that occur in individuals with diabetes, due to poor circulation, neuropathy, and impaired wound healing. They can lead to severe infections, gangrene, and even amputation. Approximately 19% to 34% of individuals with diabetes are expected to develop DFU during their lifetime. Treatments include wound care, infection control, offloading pressure, and improving blood sugar control. Advanced treatments include skin grafts, hyperbaric oxygen therapy, and growth factor therapies. Despite all these treatment options, DFUs remain a significant medical challenge, with a healing rate of only 75%, 17% require amputation. In addition, there is a significant increase in mortality rates among patients with DFUs, surpassing that of diabetes alone. There are approximately 1.2M new DFU patients per year in the US alone, with an average treatment cost of $20,000, and severe cases (resulting in amputations) costing > $40K. The global yearly market is estimated at $7.6 Billion.

About Cytora

Established in 2018, Cytora is a biopharmaceutical company at the forefront of stem cell therapy. Cytora developed a revolutionary technology to produce off-the-shelf (allogeneic) therapeutic doses of human Oral Mucosa Stem Cells to treat challenging diseases, including chronic wounds such as incurable diabetic foot ulcers (DFUs) and degenerative diseases such as Parkinson’s Disease, Multiple System Atrophy (MSA), and Alzheimer’s Disease. The Company successfully completed a Phase 1/2a study for treating DFUs and is currently conducting a Phase 1 study for the treatment of MSA. Cytora’s technology platform is based on the discoveries of Prof. Sandu Pitaru, Faculty of Medicine, School of Dentistry at the Tel Aviv University in Israel, who is also the scientific founder of the Company. For additional information, please visit www.cytorastem.com.

Media contact:

Tsipi Haitovsky
Global Media Liaison
+972-52-598-9892
Tsipihai5@gmail.com

1 Arie I, Pal A, et al., 2024. The Lamina Propria of the Oral Mucosa Harbors a Neural Crest-Like Stem Cell Population Resistant to Hyperglycemia Induced by Diabetes Type II, Medical Research Archives, [online] 12(5). https://doi.org/10.18103/mra.v12i5.5181

View original content:https://www.prnewswire.com/news-releases/cytora-reports-successful-results-of-phase-12a-trial-of-stem-cell-treatment-for-diabetic-foot-ulcers-302424359.html

SOURCE Cytora